RedHill Biopharma - FDA approves Talicia for H. pylori
RedHill Biopharma announced yesterday that the FDA has approved Talicia for the treatment of H. pylori infection in adults. The label is broad and potentially positions Talicia to compete as a front-line treatment. Talicia now is the only rifabutin-based combination antibiotic treatment approved by the FDA. In two Phase III clinical trials conducted by RedHill, no resistance to rifabutin was observed, which will be the key competitive advantage compared to standard-of-care clarithromycin-based H. pylori treatment. We previously assigned a high likelihood (90%) of successful approval given the good efficacy data and clean safety profile. Our last published RedHill valuation was $556m or $15.8 per ADS, which we increase to $571m or $16.2 per ADS following the removal of the remaining probability of success from our model.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.